Table 2.

Modulation of molecular targets of oncogenic miRs downregulated by three to five CUR, EGCG, QUE, RES and GEN.

miRs	miR-20a	miR-21	miR-25	miR-27a	miR-93	miR-106b	miR-155	miR-221
Polyphenols	CGA Huang et al. [46] CUR Gandhy et al. [47] EGCG Mirzaaghaei et al. [48] RES Dhar et al. [49]; Dhar et al. [50]	CGA Wang et al. [51] CUR Mudduluru et al. [52]; Subramaniam et al. [53]; Zhang et al. [54]; Taverna et al. [55]; Yallapu et al. [56] EGCG Fix et al. [57] **; Siddiqui et al. [58] GEN Zaman et al. [59] RES Tili et al. [60]; Sheth et al. [61]; Liu et al. [62]; Li et al. [63]; Zhou et al. [64]	CUR Sun et al. [15] EGCG Fix et al. [57] **; Gordon et al. [34]; Zan et al. [65] RES Tili et al. [60]	CUR Toden et al. [22]; Noratto et al. [66] EGCG Fix et al. [57] ** GEN Xia et al. [67]; Xu et al. [68]; Sun et al. [69]	CGA Huang et al. [46] EGCG Chakrabarti et al. [23]; Chakrabarti et al. [24] RES Singh et al. [70]	CGA Huang et al. [46] EGCG Chakrabarti et al. [23] RES Dhar et al. [50]; Dhar et al. [49]	CGA Zeng et al. [71] CUR Ma et al. [72] GEN de la Parra et al. [73] QUE Boesch-Saadatmandi et al. [74] RES Tili et al. [75]	CUR Zhang et al. [76]; Allegri et al. [77] EGCG Allegri et al. [77] GEN Chen et al. [78]
Targets *	p21↑ CGA: Huang et al. [46] PTEN↑ RES: Dhar et al. [49]	Smad7↑ CGA: Wang et al. [51] PDCD4↑ CUR: Mudduluru et al. [52] PTEN↑ CUR: Zhang et al. [54] PTEN↑ CUR: Taverna et al. [55] p21↑, p38 MAPK↑, Cyclin E2↓ GEN: Zaman et al. [59] PDCD4↑ RES: Sheth et al. [61] Bcl-2↓ RES: Liu et al. [62] NF-κB↓ RES: Liu et al. [63] AKT↓, Bcl-2↓ RES: Zhou et al. [64]	p53↑ EGCG: Gordon et al. [34] PARP1↑, Caspases 3↑, Caspases 9↑ EGCG: Zan et al. [65]	Cyclin E1↓, c-Myc↓ via FBXW7 CUR: Toden et al. [22] ZBTB10-Sp↑ CUR: Noratto et al. [66] Sp1↓, Sp3↓ Sp4↓, EGFR↓, hepatocyte growth factor receptor↓, survivin↓, Bcl-2↓, Cyclin D1↓, NFκB↓, ZBTB4↑ CUR: Grandhy et al. [47] Spry2↑ GEN: Xu et al. [68]	p21↑ CGA: Huang et al. [46] Caspase 8↑, tBid↑, Calpain↑, Caspase 3↑ EGCG: Chakrabarti et al. [23]	p21↑ CGA: Huang et al. [46] PTEN↑ RES: Dhar et al. [50]; Dhar et al. [49]	Inflammation↓ via NF-κB/NLRP3 CGA: Zeng et al. [71] SOCS1↓, IL-6↓, CUR: Ma et al. [72] PTEN↑, FOXO3a↑ GEN: de la Parra et al. [73] AP-1↓ via miR-663 RES: Tili et al. [75]	PTEN↑, p27↑, p57↑, PUMA↑ CUR: Sarkar et al. [79] FGF2↓, MMP2↓, VEGF↓, HGF↓, CUR: Zhang et al. [76] miR-21↓, miR-146b↓, miR-221↓, miR-222↓ CUR: Allegri et al. [77] miR-221↓, EGCG: Allegri et al. [77] ARHI↑ GEN:Chen et al. [78]

* Targets upregulated and downregulated by polyphenols through downregulation of miRs are indicated by ↑ and ↓, respectively. ** EGCG-rich Polyphenon-E. PTEN; phosphatase and tensin homolog deleted on chromosome 10, Smad; Small mother against decapentaplegic, PDCD; programmed cell death, Bcl-2; B-cell lymphoma 2, NF-κB; nuclear factor-κB, AKT; AKT serine/threonine kinase 1, PARP; poly(ADP-ribose) polymerase 1, FBXW7; F-Box And WD Repeat Domain Containing 7, ZBTB10; Zinc finger and BTB domain containing 10, Sp1; specificity protein 1, EGFR; epidermal growth factor receptor, Spry2; Sprouty RTK signaling antagonist 2, tBid; truncated BH3 interacting domain death agonist, NLRP3; NLR family, pyrin domain containing 3, SOCS1; suppressor of cytokine signal 1, IL-6; interleukin-6, FOXO3a; forkhead Box O3, AP-1; Activator protein 1, PUMA; p53-upregulated modulator of apoptosis, ARHI; age-related hearing impairment, FGF2; fibroblast growth factor 2, MMP; matrix metalloproteinase, VEGF; vascular endothelial growth factor, HGF; hepatocyte growth factor.